Dexcom
S&P 500
Nasdaq 100
$83.03
-1.75%
Delayed · cached 15 min
Fair value analysis
DXCM
Dexcom
$83.03
Close used for this calculation
$46.31Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
54/100
Quality radar
Consensus fair value
$46.31
Above FV▼ -44.2% against the close used
Model range $23.60 – $53.43
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear$23.60Fair value$46.31Bull$53.43
FairClose
52-week traded range
52W low $54.8452W high $92.34
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading above the consensus fair value
Dexcom closed at $83.03, 79.3% above the consensus fair value of $46.31 drawn from 7 valuation models.
Financial DNA score 54/100 — Good. P/E of 39.7x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
$53.43
-35.6%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
P/E Fair Value
$41.80
-49.7%
EPS × 20x (sector P/E)
EPS=2.09, Sector P/E=20x
Peter Lynch (PEG)
$23.60
-71.6%
EPS × Growth% (PEG = 1 is fair)
EPS=2.09, g=11.3%
EV/EBITDA
$45.49
-45.2%
(EBITDA × 15.6x − Net Debt) ÷ Shares
EBITDA=1.16B
Book Value (P/B)
$43.50
-47.6%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=6.72, ROE=31.9%, g=6%, r=10%
Reverse DCF
$83.03
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 16.4% | Historical: 11.3%
Margin of Safety
$35.71
-57.0%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=47.61, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.